Skip to main content
. 2024 Nov 18;15(12):2210–2219. doi: 10.1021/acsmedchemlett.4c00481

Figure 2.

Figure 2

Previously published compounds that emerged from optimization of high-throughput screening hits: clinical candidate VU0424238 (auglurant, 10) and backup scaffold 11. Further optimization led to potent mGlu5 NAMs 12.